Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt

Sanofi is getting a big part of its late-stage clinical program for fitusiran back on track after working out an agreement with the FDA on a new set of protocols. They’re getting back into the clinic with adult and adolescent patients.